Synonym
IM-250; IM 250; IM250
IUPAC/Chemical Name
(S)-2-(2',5'-difluoro-[1,1'-biphenyl]-4-yl)-N-methyl-N-(4-methyl-5-(S-methylsulfonimidoyl)thiazol-2-yl)acetamide
InChi Key
JDZTWDISDHLKCR-LJAQVGFWSA-N
InChi Code
InChI=1S/C20H19F2N3O2S2/c1-12-19(29(3,23)27)28-20(24-12)25(2)18(26)10-13-4-6-14(7-5-13)16-11-15(21)8-9-17(16)22/h4-9,11,23H,10H2,1-3H3/t29-/m0/s1
SMILES Code
O=C(N(C)C1=NC(C)=C([S@](=N)(C)=O)S1)CC2=CC=C(C3=CC(F)=CC=C3F)C=C2
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
IM-250 is a potent HSV-1 helicase primase inhibitor. Helicase-primase inhibitors (HPIs) are a class of antiviral drugs that target the
helicase-primase complex of herpes simplex virus 1 (HSV-1) and other viruses. This complex is involved in DNA replication,
separating double DNA strands into single strands during DNA synthesis.
In vitro activity:
In vitro chemosusceptibility assays demonstrated the superior efficacy of helicase-primase inhibitors (HPI) and the drug candidate IM250 over acyclovir (ACV) against HSV-1 isolates from affected patients, suggesting potential therapeutic benefits from ACV/HPI
combinations in treating HSV-induced ALF.The development of new approaches like the helicase-primase inhibitor IM-250 exhibit
potent in vitro anti-herpes activity with low resistance, improved tissue exposure, and efficacy in animal models, suggesting promise
as a therapeutic option for chronic HSV infections, including those resistant to nucleoside drugs.
In vivo activity:
Herpes is a widespread infection causing lifelong issues despite current treatments only targeting active infections, leaving the latent
viral reservoir untouched. A helicase-primase inhibitor (HPI) called IM-250 shows promise in targeting chronic neuronal HSV
infections in animal models, reducing recurrences when administered during latency periods. This challenges the common belief that
latent reservoirs are inaccessible to treatment, suggesting a potential shift in how we approach therapy for latent neuronal HSV
infections.
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMSO |
4.4 |
10.00 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
435.51
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
Spahn S, Riessen R, Berg CP, Malek NP, Emrich MH, Lohrengel K, Ganzenmueller T, Iftner T, Kleymann G, Hamprecht K.
Comprehensive clinical and virological characterization of three cases of fulminant liver failure owing to HSV1 primary
infection. Liver Int. 2022 May;42(5):1005-1011. doi: 10.1111/liv.15215. Epub 2022 Mar 7. PMID: 35230726.
2. Gege C, Bravo FJ, Uhlig N, Hagmaier T, Schmachtenberg R, Elis J, Burger-Kentischer A, Finkelmeier D, Hamprecht K,
Grunwald T, Bernstein DI, Kleymann G. A helicase-primase drug candidate with sufficient target tissue exposure affects
latent neural herpes simplex virus infections. Sci Transl Med. 2021 Jun 16;13(598):eabf8668. doi:
10.1126/scitranslmed.abf8668. PMID: 34135112.
Bernstein DI, Sawtell NM, Bravo FJ, Dixon DA, Gege C, Kleymann G. Intermittent therapy with helicase-primase inhibitor
IM-250 efficiently controls recurrent herpes disease and reduces reactivation of latent HSV. Antiviral Res. 2023
Nov;219:105733. doi: 10.1016/j.antiviral.2023.105733. Epub 2023 Oct 18. PMID: 37858763.. Uhlig N, Donner AK, Gege C, Lange F, Kleymann G, Grunwald T. Helicase primase inhibitors (HPIs) are efficacious for
therapy of human herpes simplex virus (HSV) disease in an infection mouse model. Antiviral Res. 2021 Nov;195:105190.
doi: 10.1016/j.antiviral.2021.105190. Epub 2021 Oct 16. PMID: 34666109.
In vitro protocol:
Spahn S, Riessen R, Berg CP, Malek NP, Emrich MH, Lohrengel K, Ganzenmueller T, Iftner T, Kleymann G, Hamprecht K.
Comprehensive clinical and virological characterization of three cases of fulminant liver failure owing to HSV1 primary
infection. Liver Int. 2022 May;42(5):1005-1011. doi: 10.1111/liv.15215. Epub 2022 Mar 7. PMID: 35230726.
2. Gege C, Bravo FJ, Uhlig N, Hagmaier T, Schmachtenberg R, Elis J, Burger-Kentischer A, Finkelmeier D, Hamprecht K,
Grunwald T, Bernstein DI, Kleymann G. A helicase-primase drug candidate with sufficient target tissue exposure affects
latent neural herpes simplex virus infections. Sci Transl Med. 2021 Jun 16;13(598):eabf8668. doi:
10.1126/scitranslmed.abf8668. PMID: 34135112.
In vivo protocol:
. Uhlig N, Donner AK, Gege C, Lange F, Kleymann G, Grunwald T. Helicase primase inhibitors (HPIs) are efficacious for
therapy of human herpes simplex virus (HSV) disease in an infection mouse model. Antiviral Res. 2021 Nov;195:105190.
doi: 10.1016/j.antiviral.2021.105190. Epub 2021 Oct 16. PMID: 34666109.
Bernstein DI, Sawtell NM, Bravo FJ, Dixon DA, Gege C, Kleymann G. Intermittent therapy with helicase-primase inhibitor
IM-250 efficiently controls recurrent herpes disease and reduces reactivation of latent HSV. Antiviral Res. 2023
Nov;219:105733. doi: 10.1016/j.antiviral.2023.105733. Epub 2023 Oct 18. PMID: 37858763.
1: Bernstein DI, Sawtell NM, Bravo FJ, Dixon DA, Gege C, Kleymann G. Intermittent therapy with helicase-primase inhibitor IM-250 efficiently controls recurrent herpes disease and reduces reactivation of latent HSV. Antiviral Res. 2023 Nov;219:105733. doi: 10.1016/j.antiviral.2023.105733. Epub 2023 Oct 18. PMID: 37858763.
2: Gege C, Kleymann G. Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus infections - structure proposal for Phaeno Therapeutics drug candidate HN0037. Expert Opin Ther Pat. 2022 Sep;32(9):933-937. doi: 10.1080/13543776.2022.2113873. Epub 2022 Aug 19. PMID: 35965439.
3: Spahn S, Riessen R, Berg CP, Malek NP, Emrich MH, Lohrengel K, Ganzenmueller T, Iftner T, Kleymann G, Hamprecht K. Comprehensive clinical and virological characterization of three cases of fulminant liver failure owing to HSV1 primary infection. Liver Int. 2022 May;42(5):1005-1011. doi: 10.1111/liv.15215. Epub 2022 Mar 7. PMID: 35230726.
4: Uhlig N, Donner AK, Gege C, Lange F, Kleymann G, Grunwald T. Helicase primase inhibitors (HPIs) are efficacious for therapy of human herpes simplex virus (HSV) disease in an infection mouse model. Antiviral Res. 2021 Nov;195:105190. doi: 10.1016/j.antiviral.2021.105190. Epub 2021 Oct 16. PMID: 34666109.
5: Gege C, Bravo FJ, Uhlig N, Hagmaier T, Schmachtenberg R, Elis J, Burger- Kentischer A, Finkelmeier D, Hamprecht K, Grunwald T, Bernstein DI, Kleymann G. A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections. Sci Transl Med. 2021 Jun 16;13(598):eabf8668. doi: 10.1126/scitranslmed.abf8668. PMID: 34135112.
